P1098: A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL) by Daniel Hodson, Geoffrey Shouse, Ho-Jin Shin, Antonio Salar Silvestre, Sabela Bobillo Varela, Vincent Ribrag, Nicol Macpherson, Raul Cordoba, Jin Seok Kim, John Radford, Stephanie Guidez, Alex F. Herrera, Franck Morschhauser, Dachelle Johnson, Macarena Izuzquiza, Nisha Sambamurthy, Alessandra Forcina, Gullu Gorgun, Robert Chen, Anas Younes, Michael Wang, Wong Seog Kim

Get full text